Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications

Human Epidermal growth factor Receptor 2 (HER2) overexpression or HER2 gene amplification defines a subset of breast cancers (BCs) characterized by higher biological and clinical aggressiveness. The introduction of anti-HER2 drugs has remarkably improved clinical outcomes in patients with both early...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligorio, Francesca, Zambelli, Luca, Fucà, Giovanni, Lobefaro, Riccardo, Santamaria, Marzia, Zattarin, Emma, de Braud, Filippo, Vernieri, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908398/
https://www.ncbi.nlm.nih.gov/pubmed/35281350
http://dx.doi.org/10.1177/17588359221079123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908398/
https://www.ncbi.nlm.nih.gov/pubmed/35281350
http://dx.doi.org/10.1177/17588359221079123

Ejemplares similares